Literature DB >> 16779724

Common polymorphisms of toll-like receptors 4 and 9 are associated with the clinical manifestation of malaria during pregnancy.

Frank P Mockenhaupt1, Lutz Hamann, Christiane von Gaertner, George Bedu-Addo, Cordula von Kleinsorgen, Ralf R Schumann, Ulrich Bienzle.   

Abstract

Toll-like receptors (TLRs) are involved in recognition of and response to Plasmodium falciparum. In 304 primiparous Ghanaian women, we examined whether common TLR4 and TLR9 polymorphisms influence susceptibility to and manifestation of malaria during pregnancy. The TLR variants did not affect P. falciparum prevalence or parasite density. However, in P. falciparum-infected women, both the TLR4 Asp299Gly and the TLR9 T-1486C polymorphisms increased the risk of low birth weight in term infants 6-fold, and, additionally, TLR4 Asp299Gly increased the risk of maternal anemia 5-fold; preterm delivery was not associated with these TLR variants. These findings suggest that TLR4 and TLR9 play a role in the manifestation of malaria during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16779724     DOI: 10.1086/505152

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  61 in total

Review 1.  TLR4 polymorphisms and disease susceptibility.

Authors:  Mamoona Noreen; Muhammad Ali A Shah; Sheeba Murad Mall; Shazia Choudhary; Tahir Hussain; Iltaf Ahmed; Syed Fazal Jalil; Muhammad Imran Raza
Journal:  Inflamm Res       Date:  2012-01-26       Impact factor: 4.575

Review 2.  Into the eye of the cytokine storm.

Authors:  Jennifer R Tisoncik; Marcus J Korth; Cameron P Simmons; Jeremy Farrar; Thomas R Martin; Michael G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2012-03       Impact factor: 11.056

Review 3.  Malarial fever: hemozoin is involved but Toll-free.

Authors:  Ralf R Schumann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-01       Impact factor: 11.205

Review 4.  Pathogen recognition and inflammatory signaling in innate immune defenses.

Authors:  Trine H Mogensen
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

5.  Genetic differentiation of populations residing in areas of high malaria endemicity in India.

Authors:  Swapnil Sinha; Vandana Arya; Sarita Agarwal; Saman Habib
Journal:  J Genet       Date:  2009-04       Impact factor: 1.166

6.  TLR9 polymorphisms are associated with altered IFN-gamma levels in children with cerebral malaria.

Authors:  Nadia A Sam-Agudu; Jennifer A Greene; Robert O Opoka; James W Kazura; Michael J Boivin; Peter A Zimmerman; Melissa A Riedesel; Tracy L Bergemann; Lisa A Schimmenti; Chandy C John
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

7.  Malaria primes the innate immune response due to interferon-gamma induced enhancement of toll-like receptor expression and function.

Authors:  Bernardo S Franklin; Peggy Parroche; Marco Antonio Ataíde; Fanny Lauw; Catherine Ropert; Rosane B de Oliveira; Dhelio Pereira; Mauro Shugiro Tada; Paulo Nogueira; Luiz Hildebrando Pereira da Silva; Harry Bjorkbacka; Douglas T Golenbock; Ricardo T Gazzinelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

8.  Risk factors for placental malaria and associated adverse pregnancy outcomes in Rufiji, Tanzania: a hospital based cross sectional study.

Authors:  Rabi Ndeserua; Adinan Juma; Dominic Mosha; Jaffu Chilongola
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

Review 9.  Immunomodulation in Plasmodium falciparum malaria: experiments in nature and their conflicting implications for potential therapeutic agents.

Authors:  Anne E P Frosch; Chandy C John
Journal:  Expert Rev Anti Infect Ther       Date:  2012-11       Impact factor: 5.091

10.  Toll-like receptor polymorphisms in malaria-endemic populations.

Authors:  Jennifer A Greene; Ann M Moormann; John Vulule; Moses J Bockarie; Peter A Zimmerman; James W Kazura
Journal:  Malar J       Date:  2009-03-24       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.